Skip to content

Ravulizumab PK and independent C5 decay coordinates

Six fixed references combine supplied apparent one-compartment PK with an independent exponential C5 coordinate, separate drug and concentration-coordinate accounting, and explicit nominal calendars.

Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder ↗

Frontiers in Neurology

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How do ravulizumab weight-band regimens connect drug and free C5?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Fixed supplied 40 to <60 kg · calendar A

Fixed one-compartment apparent PK and independent autonomous C5 decay coordinate under a supplied bolus calendar. Drug exposure does not control the C5 coordinate.

0–352 day

Scenario details

Fixed supplied 40 to <60 kg · calendar A

Fixed one-compartment apparent PK and independent autonomous C5 decay coordinate under a supplied bolus calendar. Drug exposure does not control the C5 coordinate.

Readouts

Ravulizumab concentration · ug/mL
Conditional serum PK concentration
Free C5 · ug/mL
Exact retained coordinate/readout alias of the fixed mathematical reference.
Accounted drug · mg
Current plus eliminated apparent drug amount
Accounted C5 coordinate · ug/mL
Independent concentration-coordinate accounting; not a binding mass balance

Study purpose

  • How do the model's key biological readouts change under fixed supplied 40 to <60 kg · calendar a?

Assumptions

  • Conditional fixed coefficients and course-level central boluses.
  • Autonomous C5 decay has no ravulizumab-dependent suppression, binding, target turnover or recovery.
  • The supplied coordinate behavior does not identify individual or population PK/PD predictions.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
day
day
352 → 168

Time between reported samples.

day

1 change · Variation 1

Continue in the background and keep the result.

Biology

Six fixed references combine supplied apparent one-compartment PK with an independent exponential C5 coordinate, separate drug and concentration-coordinate accounting, and explicit nominal calendars.

Six fixed references combine supplied apparent one-compartment PK with an independent exponential C5 coordinate, separate drug and concentration-coordinate accounting, and explicit nominal calendars.

Model details

7 parameters · 6 states · 6 equations · 20 derived outputs

Classification & API access
Therapeutic
Ravulizumab
Modality
Monoclonal antibody
Target
Complement C5
Disease / scope
Neuromyelitis optica spectrum disorder
ParameterDefaultUnitDescription
Apparent distribution volumeapparent_volume_l2.875598785140861LFixed supplied mathematical coefficient; no recovered population estimate or editable domain.
Fixed C5 decay coordinate starting referencebaseline_free_c5_ug_ml120.1µg/mLFixed reported reference annotation used only in nonfeedback diagnostics.
Reported free C5 reference concentrationcomplete_c5_inhibition_threshold_ug_ml0.5µg/mLFixed reported reference annotation used only in nonfeedback diagnostics.
Reported free C5 assay lower quantification limitfree_c5_assay_lloq_ug_ml0.0183µg/mLFixed reported reference annotation used only in nonfeedback diagnostics.
C5 suppression ratek_c5_suppression_per_day8.67181/dayFixed supplied mathematical coefficient; no recovered population estimate or editable domain.
Elimination rate constantkel_per_day0.016703366423785561/dayFixed supplied mathematical coefficient; no recovered population estimate or editable domain.
Reported serum ravulizumab reference concentrationtherapeutic_threshold_ug_ml175µg/mLFixed reported reference annotation used only in nonfeedback diagnostics.

Related models

Eculizumab fixed PK and authored response diagnosticsSB12/eculizumab fixed-group PK/PD referenceSecukinumab fixed PK and response-coordinate referenceRituximab exposure and CD19-positive B-cell dynamics

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics